中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 12
Dec.  2024
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(12): 2484-2491

Efficacy and safety of N-acetylcysteine in treatment of severe alcoholic hepatitis

DOI: 10.12449/JCH241219
  • 1.

    Senior Department of Hepatology，The Fifth Medical Center of Chinese PLA General Hospital，Beijing 100039，China

  • 2.

    Second Department of Hepatology，Qingdao Sixth People’s Hospital，Qingdao，Shandong 266033，China

Research funding:

National Science and Technology Major Project (2017ZX10203201004);

Beijing Science and Technology Plan Project (Z151100003915156)

More Information
  • Corresponding author: ZHU Bing， zhubing302@163.com （ORCID： 0000-0003-0190-6384）
  • Received Date: 2024-04-04
  • Accepted Date: 2024-06-06
  • Published Date: 2024-12-25
    Abstract
  •   Objective  To investigate the efficacy and safety of N-acetylcysteine （NAC） in the treatment of severe alcoholic hepatitis （SAH）， and to provide a basis for clinical medication for SAH.  Methods  A prospective randomized controlled trial was conducted among 172 SAH patients with a Maddrey discriminant function score of >32 points who were recruited by The Fifth Medical Center of Chinese PLA General Hospital from June 2015 to June 2018， and these patients were divided into NAC group with 84 patients and control group with 86 patients. NAC （8 g/day， 28 days） was assessed in terms of its safety in SAH patients， its impact on 28-day biochemical parameters， and its role in improving 28- and 180-day survival rates. A further analysis was performed to investigate the effect of NAC on the 28- and 180-day survival rates of SAH patients with acute-on-chronic liver failure （ACLF-SAH patients） and those without acute-on-chronic liver failure （non-ACLF-SAH patients）. The independent-samples t test was used for comparison of normally distributed continuous data between two groups， and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups. The Kaplan-Meier method was used to plot survival curves， and the Log-rank test was used for comparison of survival curves. Univariate and multivariate Cox proportional-hazards regression model analyses were used to investigate independent influencing factors.  Results  No serious adverse events were observed during NAC treatment， suggesting that NAC had a good safety profile. Compared with the control group， NAC did not significantly improve the 28-day biochemical parameters （all P>0.05） and survival rate of SAH patients （P=0.081）， but it could improve the 180-day survival rate of SAH patients （67.4% vs 81.0%， χ2=4.280， P=0.039）. NAC did not improve the 28- and 180-day survival rates of ACLF-SAH patients （both P>0.05）； NAC did not improve the 28-day survival rate of non-ACLF-SAH patients （P>0.05）， but it could improve the 180-day survival rate of these patients （68.4% vs 88.9%， χ2=4.883， P=0.027）. The multivariate Cox regression survival analysis showed that NAC treatment （hazard ratio ［HR］=2.530， 95% confidence interval ［CI］： 1.334‍ ‍— 4.796， P=0.004，）， Maddrey discriminant function score （HR=3.852， 95%CI： 2.032 — 7.304， P<0.001）， and serum sodium level （HR=1.948， 95%CI： 1.079‍ ‍—‍ ‍3.517， P=0.027） were independent influencing factors for 180-day survival rate in SAH patients.  Conclusion  NAC has a good safety profile in the treatment of SAH and can improve the 180-day survival rate of SAH patients， and in particular， non-ACLF-SAH patients can benefit from NAC treatment in terms of middle- and long-term survival rates.

     

    • FullText(HTML)
  • loading
    • References(21)
  • [1]
    YOU SL, RONG YH, ZHU B, et al. Changing etiology of liver failure in 3, 916 patients from Northern China: A 10-year survey[J]. Hepatol Int, 2013, 7( 2): 714- 720. DOI: 10.1007/s12072-013-9424-5.
    [2]
    ZHU B, YOU SL, LIU HL, et al. Analysis of etiology and prognosis of liver failure in 623 elderly patients[J]. Med J Chin People’s Liberation Army, 2014, 39( 8): 624- 627. DOI: 10.11855/j.issn.0577-7402.2014.08.06.

    朱冰, 游绍莉, 刘鸿凌, 等. 623例老年肝衰竭病因学及预后分析[J]. 解放军医学杂志, 2014, 39( 8): 624- 627. DOI: 10.11855/j.issn.0577-7402.2014.08.06.
    [3]
    LIU JJ, ZHANG MY, SUN YM, et al. Evolution in the indications for anti-viral therapy in chronic hepatitis B[J]. J Clin Hepatol, 2023, 39( 6): 1299- 1303. DOI: 10.3969/j.issn.1001-5256.2023.06.007.

    刘津津, 张梦阳, 孙亚朦, 等. 慢性乙型肝炎抗病毒治疗适应证的变迁[J]. 临床肝胆病杂志, 2023, 39( 6): 1299- 1303. DOI: 10.3969/j.issn.1001-5256.2023.06.007.
    [4]
    CAO XZ, YI W, WANG FC, et al. Mother-to-child blockade with telbivudine of pregnant women infected with hepatitis B virus and the influence on the immune response to hepatitis B vaccine of infants[J/CD]. Chin J Exp Clin Infect Dis(Electronic Edition), 2022, 16( 3): 158- 164. DOI: 10.3877/cma.j.issn.1674-1358.2022.03.003.

    曹秀贞, 易为, 王夫川, 等. 乙型肝炎病毒感染孕妇替比夫定母婴阻断及其对婴儿乙肝疫苗免疫应答的影响[J/CD]. 中华实验和临床感染病杂志(电子版), 2022, 16( 3): 158- 164. DOI: 10.3877/cma.j.issn.1674-1358.2022.03.003.
    [5]
    SUN FR, WANG BY. Severe alcoholic hepatitis and acute-on-chronic liver failure[J]. J Clin Hepatol, 2019, 35( 3): 489- 493. DOI: 10.3969/j.issn.1001-5256.2019.03.008.

    孙福荣, 王炳元. 重症酒精性肝炎与慢加急性肝衰竭[J]. 临床肝胆病杂志, 2019, 35( 3): 489- 493. DOI: 10.3969/j.issn.1001-5256.2019.03.008.
    [6]
    European Association for the Study of the Liver. EASL clinical practice guidelines: Management of alcohol-related liver disease[J]. J Hepatol, 2018, 69( 1): 154- 181. DOI: 10.1016/j.jhep.2018.03.018.
    [7]
    RAMOND MJ, POYNARD T, RUEFF B, et al. A randomized trial of prednisolone in patients with severe alcoholic hepatitis[J]. N Engl J Med, 1992, 326( 8): 507- 512. DOI: 10.1056/NEJM199202203260802.
    [8]
    SINGAL AK, BATALLER R, AHN J, et al. ACG clinical guideline: Alcoholic liver disease[J]. Am J Gastroenterol, 2018, 113( 2): 175- 194. DOI: 10.1038/ajg.2017.469.
    [9]
    Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure(2018)[J]. J Clin Hepatol, 2019, 35( 1): 38- 44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.

    中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版)[J]. 临床肝胆病杂志, 2019, 35( 1): 38- 44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.
    [10]
    MATHURIN P, O’GRADY J, CARITHERS RL, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: Meta-analysis of individual patient data[J]. Gut, 2011, 60( 2): 255- 260. DOI: 10.1136/gut.2010.224097.
    [11]
    THURSZ MR, RICHARDSON P, ALLISON M, et al. Prednisolone or pentoxifylline for alcoholic hepatitis[J]. N Engl J Med, 2015, 372( 17): 1619- 1628. DOI: 10.1056/NEJMoa1412278.
    [12]
    LOUVET A, WARTEL F, CASTEL H, et al. Infection in patients with severe alcoholic hepatitis treated with steroids: Early response to therapy is the key factor[J]. Gastroenterology, 2009, 137( 2): 541- 548. DOI: 10.1053/j.gastro.2009.04.062.
    [13]
    MATHURIN P, LOUVET A, DUHAMEL A, et al. Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: A randomized clinical trial[J]. JAMA, 2013, 310( 10): 1033- 1041. DOI: 10.1001/jama.2013.276300.
    [14]
    YANG YM, CHO YE, HWANG S. Crosstalk between oxidative stress and inflammatory liver injury in the pathogenesis of alcoholic liver disease[J]. Int J Mol Sci, 2022, 23( 2): 774. DOI: 10.3390/ijms23020774.
    [15]
    DEY A, CEDERBAUM AI. Alcohol and oxidative liver injury[J]. Hepatology, 2006, 43(2 Suppl 1): S63- S74. DOI: 10.1002/hep.20957.
    [16]
    NGUYEN-KHAC E, THEVENOT T, PIQUET MA, et al. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis[J]. N Engl J Med, 2011, 365( 19): 1781- 1789. DOI: 10.1056/NEJMoa1101214.
    [17]
    MORENO C, LANGLET P, HITTELET A, et al. Enteral nutrition with or without N-acetylcysteine in the treatment of severe acute alcoholic hepatitis: A randomized multicenter controlled trial[J]. J Hepatol, 2010, 53( 6): 1117- 1122. DOI: 10.1016/j.jhep.2010.05.030.
    [18]
    STEWART S, PRINCE M, BASSENDINE M, et al. A randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis[J]. J Hepatol, 2007, 47( 2): 277- 283. DOI: 10.1016/j.jhep.2007.03.027.
    [19]
    PHILLIPS M, CURTIS H, PORTMANN B, et al. Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis: A randomised clinical trial[J]. J Hepatol, 2006, 44( 4): 784- 790. DOI: 10.1016/j.jhep.2005.11.039.
    [20]
    MUMTAZ K, AZAM Z, HAMID S, et al. Role of N-acetylcysteine in adults with non-acetaminophen-induced acute liver failure in a center without the facility of liver transplantation[J]. Hepatol Int, 2009, 3( 4): 563- 570. DOI: 10.1007/s12072-009-9151-0.
    [21]
    NABI T, NABI S, RAFIQ N, et al. Role of N-acetylcysteine treatment in non-acetaminophen-induced acute liver failure: A prospective study[J]. Saudi J Gastroenterol, 2017, 23( 3): 169- 175. DOI: 10.4103/1319-3767.207711.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(4)  / Tables(5)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (159) PDF downloads(31) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return